Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on February 12, 2019. The filing addresses a change in the listing status of the Company's common stock on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
- Listing Transfer: The Company received approval to transfer its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective February 13, 2019.
- Compliance Status: The transfer was necessitated because the Company's stock bid price closed below the $1.00 minimum requirement for the Nasdaq Global Market for 30 consecutive business days prior to August 13, 2018.
- Symbol: The stock will continue to trade under the symbol "FLKS."
Outlook, Risks, and Contingencies
The Company has been granted an additional 180-day period to regain compliance with the Minimum Bid Price Requirement. To avoid delisting, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days before August 12, 2019.
- Reverse Stock Split: The Company may effect a reverse stock split to regain compliance. If implemented, it must be completed no later than 10 business days prior to August 12, 2019.
- Delisting Risk: If compliance is not achieved by August 12, 2019, the Company faces delisting. The Company may appeal this determination to a Nasdaq Hearings Panel, though success is not assured.
Investor Verification Checklist
- Verify the current trading status and bid price of "FLKS" on the Nasdaq Capital Market.
- Monitor announcements regarding the potential implementation of a reverse stock split before the August 2019 deadline.
- Review the Company's financial statements to understand the underlying reasons for the low stock price.
- Confirm whether the Company has filed any subsequent 8-Ks regarding the outcome of the compliance period or an appeal to the Nasdaq Hearings Panel.